Published online before print March 9, 2006, doi: 10.1161/01.STR.0000208294.46968.a4
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:1070.)
© 2006 American Heart Association, Inc.
Original Contributions |
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
From the Washington University School of Medicine (E.B.-D., B.F.G.), St. Louis, Mo; New York University School of Medicine (M.J.R.), New York, NY; Centers for Medicare and Medicaid Services (D.S.N.), Dallas, Tex.
Correspondence to Brian F. Gage, MD, MSc, Division of General Medical Sciences, Washington University School of Medicine, Campus Box 8005, 660 S Euclid, St. Louis, MO 63110. E-mail: bgage{at}im.wustl.edu
Background and Purpose— More than 2 million Americans have atrial fibrillation, and without antithrombotic therapy, their stroke rate is increased 5-fold. In randomized controlled trials, warfarin prevented 65% of ischemic strokes (hazard ratio [HR], 0.35; 95% CI, 0.26 to 0.48) compared with no antithrombotic therapy. However, the effectiveness of warfarin therapy outside of clinical trials is unknown, especially in black and Hispanic populations. Our goal was to quantify use of warfarin therapy, frequency of International Normalized Ratio monitoring, and effectiveness for stroke prophylaxis in Medicare beneficiaries with atrial fibrillation.
Methods— This was a cohort study of Medicare beneficiaries with atrial fibrillation who were hospitalized between March 1998 and April 1999 in all 50 US states. The primary outcome was incident hospitalizations for ischemic stroke based on validated International Classification of Diseases, 9th Revision, Clinical Modification codes.
Results— Two thirds of ideal anticoagulation candidates were prescribed warfarin on hospital discharge. In unadjusted analyses, the stroke rates per 100 patient years of warfarin therapy were 5.2 in (non-Hispanic) white Medicare beneficiaries, 10.6 in black beneficiaries, and 12.2 in Hispanic beneficiaries. After adjusting for comorbid conditions, warfarin prescription was more frequent and monitoring more regular in white Medicare beneficiaries than in black or Hispanic beneficiaries (P<0.0001). Warfarin use was associated with 35% fewer ischemic strokes (HR, 0.65; 95% CI, 0.55 to 0.76) compared with no antithrombotic therapy but was less effective in black and Hispanic beneficiaries (P for interaction=0.048).
Conclusions— The use, monitoring, and effectiveness of warfarin therapy are suboptimal in Medicare beneficiaries, especially in black and Hispanic beneficiaries.
Key Words: atrial fibrillation • continental population groups • stroke • warfarin
This article has been cited by other articles:
 |
|
 |
|
  B. F. Gage Can We Rely on RE-LY? N. Engl. J. Med., September 17, 2009; 361(12): 1200 - 1202. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. A. Reilly, E. Themeles, J. Varrone, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation N. Engl. J. Med., September 17, 2009; 361(12): 1139 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ACTIVE Investigators Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation N. Engl. J. Med., May 14, 2009; 360(20): 2066 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat and S. J Connolly Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes Heart, January 15, 2009; 95(2): 95 - 97. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gattellari, J. Worthington, and N. Zwar Warfarin: An Inconvenient Truth Stroke, January 1, 2009; 40(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Hylek, L. Frison, L. E. Henault, and A. Cupples Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation: Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V Stroke, November 1, 2008; 39(11): 3009 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y.-J. Shen, J. F. Yao, S. S. Brar, M. B. Jorgensen, X. Wang, and W. Chen Racial/Ethnic Differences in Ischemic Stroke Rates and the Efficacy of Warfarin Among Patients With Atrial Fibrillation Stroke, October 1, 2008; 39(10): 2736 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" Circulation, February 5, 2008; 117(5): e150 - e150. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Ford, A. M. Choy, P. Deedwania, D. G. Karalis, C.-J. Lindholm, W. Pluta, L. Frison, S. B. Olsson, and on behalf of the SPORTIF III, V Investigators Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials Stroke, November 1, 2007; 38(11): 2965 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]
|
|